Researchers reported a Phase 1/2 trial testing autologous CD133+ bone marrow‑derived stem cells for Asherman syndrome, a fibrotic uterine condition. The trial evaluated feasibility, safety and early signals of endometrial regeneration using patients’ own CD133+ cells delivered to the uterus. Investigators documented procedural safety and provided histologic and functional endpoints to justify larger controlled studies. The report positions autologous CD133+ therapy as a potential regenerative option for reproductive medicine pending confirmatory efficacy data.